Procaps Group S.A. provided earnings guidance for the fiscal year ended December 31, 2022 and 2023. For the fiscal year 2022 the company currently estimate preliminary, unaudited revenues in the range of $405 - $415 million, with low reported single-digit growth, primarily driven by the positive performance of Rx, OTC product lines and CDMO products and services.

For the year 2023, The company expects to grow net revenues at approximately 10%+ in 2023 on a constant currency basis.